Monitoring Src status after dasatinib treatment in HER2+ breast cancer with (89)Zr-trastuzumab PET imaging

BACKGROUND: De novo or acquired resistance in breast cancer leads to treatment failures and disease progression. In human epidermal growth factor receptor 2 (HER2)-positive (HER2+) breast cancer, Src, a non-receptor tyrosine kinase, is identified as a major mechanism of trastuzumab resistance, with...

Descripción completa

Detalles Bibliográficos
Autores principales: McKnight, Brooke N., Viola-Villegas, Nerissa T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203283/
https://www.ncbi.nlm.nih.gov/pubmed/30359299
http://dx.doi.org/10.1186/s13058-018-1055-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203283/
https://www.ncbi.nlm.nih.gov/pubmed/30359299
http://dx.doi.org/10.1186/s13058-018-1055-2

Ejemplares similares